Top Markets
Coin of the day
NuGenerex Immuno-Oncology, Inc. NuGenerex Immuno-Oncology, Inc.

NuGenerex Immuno-Oncology, Inc.

NUGX
Rang in Aktien #41797
NuGenerex Immuno-Oncology, Inc. is an oncology firm committed to treating... NuGenerex Immuno-Oncology, Inc. is an oncology firm committed to treating cancer through the strategic modulation of the immune system. The company's development pipeline includes a range of immunotherapeutic products and vaccines. Notably, it is advancing AE37, a peptide immunotherapeutic vaccine, which is currently undergoing Phase II clinical studies for metastatic triple-negative breast cancer. Founded in 1993 and headquartered in Miramar, Florida, the entity was formerly named Antigen Express, Inc. NuGenerex Immuno-Oncology, Inc. operates as a subsidiary of Generex Biotechnology Corporation.
Aktienkurs
$0.0001
Zuletzt synchronisiert: 2023-05-22
Marktkapitalisierung
$10.03K
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel NuGenerex Immuno-Oncology, Inc. (NUGX)

Kategorie

Kursverlauf für NuGenerex Immuno-Oncology, Inc. (NUGX)
Höchster Schlusskurs: $0.00 am 2023-05-01

Niedrigster Schlusskurs: $1.44 am 2021-03-01
Kursverlauf der Aktie von NuGenerex Immuno-Oncology, Inc. von 2021 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2023 75.00%
2022 -98.81%
2021 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$527.87 33.33%
US
$873.57 35.10%
NL
$736.38 7.69%
CH
$263.09 18.09%
BE
$1.08K -6.98%
KR